Akt inhibition is effective against PTEN-deleted, chemoirradiation-resistant glioblastoma stem cells

Dimou, J; D&#39;Abaco, G; Paradiso, L; Kountouri, N; Ng, W; Stylli, S; Drummond, K; Burgess, A; Kaye, A; Morokoff, A

Author(s): Dimou, J; D'Abaco, G; Paradiso, L; Kountouri, N; Ng, W; Stylli, S; Drummond, K; Burgess, A; Kaye, A; Morokoff, A;
Details: Publication Year 2025-03-13,Volume 43,Issue #1,Page 20-36
Journal Title: Growth Factors
Abstract: Activated Akt and loss of phosphatase and tensin homolog (PTEN) tumour suppression aid chemo- and radio-resistance in glioblastoma stem cells (GSC), contributing to treatment failure in glioblastoma. In this study, sixteen GSC lines were generated from 66 individual glioma samples, in gliomasphere culture conditions. Thirteen of 16 GSC lines expressed hyperphosphorylated Akt (Ser473); Akt phosphorylation did not correlated with EGFR expression. An LDH colorimetric assay was used to measure the in vitro cytotoxicity of eight of these lines. Akt X (20 µM) proved more effective at inducing in vitro GSC cytotoxicity (range: 22-73%) over 48 hours than triciribine (20 µM) (0-27%), although both agents inhibited Akt phosphorylation as detected by western blot analysis. A statistically significant correlation between PTEN loss (western blot) and the extent of Akt X-induced cytotoxicity was found (p = 0.03). Akt inhibition reduces in vitro proliferation of treatment-resistant GSC lines, especially in PTEN-deficient lines, warranting further translational investigation in glioblastoma.; Glioblastoma stem cells (GSC) are known to be resistant to radiotherapy and temozolomide chemotherapyThis treatment resistance is driven, in part, by Pi3-kinase dysregulation and PTEN lossAn Akt inhibitor, Akt X, shows preferential in vitro cytotoxic activity against PTEN-negative GSC.; eng
Publisher: Taylor & Frances
Keywords: Akt; Glioblastoma; Pten; glioma stem cells; phenoxazine
Research Division(s): Structural Biology
PubMed ID: 40078116
Publisher's Version: https://doi.org/10.1080/08977194.2025.2470185
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2025-05-06 09:18:29

Last Modified: 2025-05-06 09:19:48